A new hope in immunotherapy for malignant gliomas: Adoptive T cell transfer therapy

Journal of Immunology Research

Volumn 2014, Issue , 2014, Pages

  Chung, Dong Sup ^a   Shin, Hye Jin ^b   Hong, Yong Kil ^b  

^a Bupyeong gu   (South Korea)

^b The Catholic University of Korea College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ADOPTIVE T CELL TRANSFER THERAPY; ANTIGEN SPECIFICITY; BLOOD BRAIN BARRIER; BONE MARROW CELL; CANCER CHEMOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL EXPANSION; CENTRAL NERVOUS SYSTEM; CYTOTOXIC T LYMPHOCYTE; EX VIVO STUDY; GAMMA DELTA T LYMPHOCYTE; GENETIC ENGINEERING; GENETICALLY MODIFIED T CELL; GLIOBLASTOMA; HOST; HUMAN; IMMUNE DEFICIENCY; IMMUNE EVASION; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; IMMUNOTHERAPY; IN VIVO STUDY; INNATE IMMUNITY; LYMPHOID CELL; LYMPHOKINE ACTIVATED KILLER CELL; MOLECULARLY TARGETED THERAPY; MYELOID DERIVED SUPPRESSOR CELL; NATURAL KILLER CELL; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); REGULATORY T LYMPHOCYTE; REVIEW; SURVIVAL; T CELL DEPLETION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TREATMENT RESPONSE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; WHOLE BODY RADIATION; ADOPTIVE IMMUNOTHERAPY; ANIMAL; BIOLOGICAL THERAPY; GLIOMA; IMMUNOLOGY; IMMUNOMODULATION; METABOLISM; T LYMPHOCYTE SUBPOPULATION;

T LYMPHOCYTE RECEPTOR;

ANIMALS; BLOOD-BRAIN BARRIER; CELL- AND TISSUE-BASED THERAPY; GLIOMA; HUMANS; IMMUNOMODULATION; IMMUNOTHERAPY, ADOPTIVE; T-CELL ANTIGEN RECEPTOR SPECIFICITY; T-LYMPHOCYTE SUBSETS; TUMOR MICROENVIRONMENT;

EID: 84903639486     PISSN: 23148861     EISSN: 23147156     Source Type: Journal    
DOI: 10.1155/2014/326545     Document Type: Review

References (245)

1. Han S. J., Zygourakis C., Lim M., Parsa A. T., Immunotherapy for Glioma. Promises and challenges. Neurosurgery Clinics of North America 2012 23 3 357 370 2-s2.0-84863006570 10.1016/j.nec.2012.05.001
2. Dietrich P.-Y., Dutoit V., Thang N. N. T., Walker P. R., T-cell immunotherapy for malignant glioma: toward a combined approach. Current Opinion in Oncology 2010 22 6 604 610 2-s2.0-77958497844 10.1097/CCO.0b013e32833dead8
3. Mitchell D. A., Fecci P. E., Sampson J. H., Adoptive immunotherapy for malignant glioma. Cancer Journal 2003 9 3 157 166 2-s2.0-0642366705 10.1097/00130404-200305000-00004
4. Paul D. B., Kruse C. A., Immunologic approaches to therapy for brain tumors. Current Neurology and Neuroscience Reports 2001 1 3 238 244 2-s2.0-0035352398
5. Schirrmacher V., Schild H.-J., Guckel B., Von Hoegen P., Tumour-specific CTL response requiring interactions of four different cell types and recognition of MHC class I and class II restricted tumour antigens. Immunology and Cell Biology 1993 71 311 326 2-s2.0-0027209208 10.1038/icb.1993.36 (Pubitemid 23253522)
6. Ochsenbein A. F., Klenerman P., Karrer U., Ludewig B., Pericin M., Hengartner H., Zinkernagel R. M., Immune surveillance against a solid tumor fails because of immunological ignorance. Proceedings of the National Academy of Sciences of the United States of America 1999 96 5 2233 2238 2-s2.0-0033514923 10.1073/pnas.96.5.2233 (Pubitemid 29117897)
7. Parmiani G., Tumor immunity as autoimmunity: tumor antigens include normal self proteins which stimulate anergic peripheral T cells. Immunology Today 1993 14 11 536 538 2-s2.0-0027431402 (Pubitemid 23316712)
8. Speiser D. E., Miranda R., Zakarian A., Bachmann M. F., McKall-Faienza K., Odermatt B., Hanahan D., Zinkernagel R. M., Ohashi P. S., Self antigens expressed by solid tumors do not efficiently stimulate naive or activated T cells: implications for immunotherapy. The Journal of Experimental Medicine 1997 186 5 645 653 2-s2.0-0030848578 10.1084/jem.186.5.645 (Pubitemid 27381529)
9. Leen A. M., Rooney C. M., Foster A. E., Improving T cell therapy for cancer. Annual Review of Immunology 2007 25 243 265 2-s2.0-34247881794 10.1146/annurev.immunol.25.022106.141527 (Pubitemid 46697909)
10. Liau L. M., Prins R. M., Kiertscher S. M., Odesa S. K., Kremen T. J., Giovannone A. J., Lin J.-W., Chute D. J., Mischet P. S., Cloughesy T. F., Roth M. D., Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clinical Cancer Research 2005 11 15 5515 5525 2-s2.0-23044479028 10.1158/1078-0432.CCR-05-0464 (Pubitemid 41060828)
11. Okada H., Lieberman F. S., Walter K. A., Lunsford L. D., Kondziolka D. S., Bejjani G. K., Hamilton R. L., Torres-Trejo A., Kalinski P., Cai Q., Mabold J. L., Edington H. D., Butterfield L. H., Whiteside T. L., Potter D. M., Schold S. C. Jr., Pollack I. F., Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of patients with malignant gliomas. Journal of Translational Medicine 2007 5, article 67 2-s2.0-40149090821 10.1186/1479-5876-5-67 (Pubitemid 351325346)
12. Phuphanich S., Wheeler C. J., Rudnick J. D., Mazer M., Wang H., Nuño M. A., Richardson J. E., Fan X., Ji J., Chu R. M., Bender J. G., Hawkins E. S., Patil C. G., Black K. L., Yu J. S., Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma. Cancer Immunology, Immunotherapy 2013 62 1 125 135 2-s2.0-84872498982 10.1007/s00262-012-1319-0
13. Wheeler C. J., Black K. L., Liu G., Mazer M., Zhang X.-X., Pepkowitz S., Goldfinger D., Ng H., Irvin D., Yu J. S., Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients. Cancer Research 2008 68 14 5955 5964 2-s2.0-48649096955 10.1158/0008-5472.CAN-07-5973
14. Cavalieri S., Cazzaniga S., Geuna M., Magnani Z., Bordignon C., Naldini L., Bonini C., Human T lymphocytes transduced by lentiviral vectors in the absence of TCR activation maintain an intact immune competence. Blood 2003 102 2 497 505 2-s2.0-0037481021 10.1182/blood-2003-01-0297 (Pubitemid 36841966)
15. Finn O. J., Persons D. A., Bendt K. M., Pirami L., Ricciardi P., Retroviral transduction of protein kinase C- γ into cytotoxic T lymphocyte clones leads to immortalization with retention of specific function. The Journal of Immunology 1991 146 4 1099 1103 2-s2.0-0026102151
16. Morgan R. A., Dudley M. E., Wunderlich J. R., Hughes M. S., Yang J. C., Sherry R. M., Royal R. E., Topalían S. L., Kammula U. S., Restifo N. P., Zheng Z., Nahvi A., De Vries C. R., Rogers-Freezer L. J., Mavroukakis S. A., Rosenberg S. A., Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006 314 5796 126 129 2-s2.0-33749624177 10.1126/science.1129003 (Pubitemid 44547756)
17. Johnson L. A., Morgan R. A., Dudley M. E., Cassard L., Yang J. C., Hughes M. S., Kammula U. S., Royal R. E., Sherry R. M., Wunderlich J. R., Lee C.-C. R., Restifo N. P., Schwarz S. L., Cogdill A. P., Bishop R. J., Kim H., Brewer C. C., Rudy S. F., VanWaes C., Davis J. L., Mathur A., Ripley R. T., Nathan D. A., Laurencot C. M., Rosenberg S. A., Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 2009 114 3 535 546 2-s2.0-70149114880 10.1182/blood-2009-03-211714
18. Eshhar Z., Waks T., Gross G., Schindler D. G., Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the γ or ζ subunits of the immunoglobulin and T-cell receptors. Proceedings of the National Academy of Sciences of the United States of America 1993 90 2 720 724 2-s2.0-0027471898 10.1073/pnas.90.2.720 (Pubitemid 23028937)
19. Bullain S. S., Sahin A., Szentirmai O., Sanchez C., Lin N., Baratta E., Waterman P., Weissleder R., Mulligan R. C., Carter B. S., Genetically engineered T cells to target EGFRvIII expressing glioblastoma. Journal of Neuro-Oncology 2009 94 3 373 382 2-s2.0-69249248185 10.1007/s11060-009-9889-1
20. Ahmed N., Salsman V. S., Kew Y., Shaffer D., Powell S., Zhang Y. J., Grossman R. G., Heslop H. E., Gottschalk S., HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors. Clinical Cancer Research 2010 16 2 474 485 2-s2.0-74549196076 10.1158/1078-0432.CCR-09-1322
21. Chow K. K., Naik S., Kakarla S., Brawley V. S., Shaffer D. R., Yi Z., Rainusso N., Wu M.-F., Liu H., Kew Y., Grossman R. G., Powell S., Lee D., Ahmed N., Gottschalk S., T cells redirected to EphA2 for the immunotherapy of glioblastoma. Molecular Therapy 2013 21 3 629 637 2-s2.0-84875215925 10.1038/mt.2012.210
22. Kahlon K. S., Brown C., Cooper L. J. N., Raubitschek A., Forman S. J., Jensen M. C., Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells. Cancer Research 2004 64 24 9160 9166 2-s2.0-10844296758 10.1158/0008-5472.CAN-04-0454 (Pubitemid 39665531)
23. Song D.-G., Ye Q., Carpenito C., Poussin M., Wang L.-P., Ji C., Figini M., June C. H., Coukos G., Powell D. J. Jr., In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB). Cancer Research 2011 71 13 4617 4627 2-s2.0-79959914449 10.1158/0008-5472.CAN-11-0422
24. Kowolik C. M., Topp M. S., Gonzalez S., Pfeiffer T., Olivares S., Gonzalez N., Smith D. D., Forman S. J., Jensen M. C., Cooper L. J. N., CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. Cancer Research 2006 66 22 10995 11004 2-s2.0-33845294816 10.1158/0008-5472.CAN-06-0160 (Pubitemid 44876999)
25. Hombach A. A., Abken H., Costimulation by chimeric antigen receptors revisited the T cell antitumor response benefits from combined CD28-OX40 signalling. International Journal of Cancer 2011 129 12 2935 2944 2-s2.0-84855186143 10.1002/ijc.25960
26. Kim T.-G., Kim C.-H., Park J.-S., Park S.-D., Kim C. K., Chung D.-S., Hong Y.-K., Immunological factors relating to the antitumor effect of temozolomide chemoimmunotherapy in a murine glioma model. Clinical and Vaccine Immunology 2010 17 1 143 153 2-s2.0-74549126817 10.1128/CVI.00292-09
27. Fadul C. E., Fisher J. L., Hampton T. H., Lallana E. C., Li Z., Gui J., Szczepiorkowski Z. M., Tosteson T. D., Rhodes C. H., Wishart H. A., Lewis L. D., Ernstoff M. S., Immune response in patients with newly diagnosed glioblastoma multiforme treated with intranodal autologous tumor lysate-dendritic cell vaccination after radiation chemotherapy. Journal of Immunotherapy 2011 34 4 382 389 2-s2.0-79955591522 10.1097/CJI.0b013e318215e300
28. MEDAWAR P. B., Immunity to homologous grafted skin; the fate of skin homografts. British Journal of Experimental Pathology 1948 29 1 58 69 2-s2.0-78651010946
29. Poltorak M., Logan S., Freed W. J., Intraventricular xenografts: chronic injection of antibodies into the CSF provokes granulomatosis reactions but Ia antibodies do not enhance graft survival. Regional Immunology 1989 2 4 197 202 2-s2.0-0024690451
30. Ludowyk P. A., Willenborg D. O., Parish C. R., Selective localisation of neuro-specific T lymphocytes in the central nervous system. Journal of Neuroimmunology 1992 37 3 237 250 2-s2.0-0026596226 10.1016/0165-5728(92)90008-9
31. Wekerle H., Sun D., Oropeza-Wekerle R. L., Meyermann R., Immune reactivity in the nervous system: modulation of T-lymphocyte activation by glial cells. The Journal of Experimental Biology 1987 132 43 57 2-s2.0-0023413923
32. Cserr H. F., Harling-Berg C. J., Knopf P. M., Drainage of brain extracellular fluid into blood and deep cervical lymph and its immunological significance. Brain Pathology 1992 2 4 269 276 2-s2.0-0026929035
33. Parney I. F., Basic concepts in glioma immunology. Advances in Experimental Medicine and Biology 2012 746 42 52 2-s2.0-84862987260 10.1007/978-1-4614-3146-6-4
34. Yang I., Han S. J., Kaur G., Crane C., Parsa A. T., The role of microglia in central nervous system immunity and glioma immunology. Journal of Clinical Neuroscience 2010 17 1 6 10 2-s2.0-72449154567 10.1016/j.jocn.2009.05.006
35. Wu A.-H., Xiao J., Anker L., Hall W. A., Gregerson D. S., Cavenee W. K., Chen W., Low W. C., Identification of EGFRvIII-derived CTL epitopes estricted by HLA A0201 for dendritic cell based immunotherapy of gliomas. Journal of Neuro-Oncology 2006 76 1 23 30 2-s2.0-30944437012 10.1007/s11060-005-3280-7
36. Sasaki M., Nakahira K., Kawano Y., Katakura H., Yoshimine T., Shimizu K., Kim S. U., Ikenaka K., MAGE-E1, a new member of the melanoma-associated antigen gene family and its expression in human glioma. Cancer Research 2001 61 12 4809 4814 2-s2.0-0035874952 (Pubitemid 32691895)
37. Scarcella D. L., Chow C. W., Gonzales M. F., Economou C., Brasseur F., Ashley D. M., Expression of MAGE and GAGE in high-grade brain tumors: a potential target for specific immunotherapy and diagnostic markers. Clinical Cancer Research 1999 5 2 335 341 2-s2.0-0033049977 (Pubitemid 29085187)
38. Ueda R., Iizuka Y., Yoshida K., Kawase T., Kawakami Y., Toda M., Identification of a human glioma antigen, SOX6, recognized by patients' sera. Oncogene 2004 23 7 1420 1427 2-s2.0-1442357201 10.1038/sj.onc.1207252 (Pubitemid 38406837)
39. Liu G., Ying H., Zeng G., Wheeler C. J., Black K. L., Yu J. S., HER-2, gp100, and MAGE-1 are expressed in human glioblastoma and recognized by cytotoxic T cells. Cancer Research 2004 64 14 4980 4986 2-s2.0-3142710121 10.1158/0008-5472.CAN-03-3504 (Pubitemid 38924546)
40. Liu G., Khong H. T., Wheeler C. J., Yu J. S., Black K. L., Ying H., Molecular and functional analysis of tyrosinase-related protein (TRP)-2 as a cytotoxic T lymphocyte target in patients with malignant glioma. Journal of Immunotherapy 2003 26 4 301 312 2-s2.0-0038167151 10.1097/00002371-200307000- 00002 (Pubitemid 36858714)
41. Wykosky J., Gibo D. M., Stanton C., Debinski W., Interleukin-13 receptor 2, EphA2, and Fos-related antigen 1 as molecular denominators of high-grade astrocytomas and specific targets for combinatorial therapy. Clinical Cancer Research 2008 14 1 199 208 2-s2.0-40749096452 10.1158/1078-0432.CCR-07-1990 (Pubitemid 351377996)
42. Hatano M., Eguchi J., Tatsumi T., Kuwashima N., Dusak J. E., Kinch M. S., Pollack I. F., Hamilton R. L., Storkus W. J., Okada H., EphA2 as a glioma-associated antigen: a novel target for glioma vaccines. Neoplasia 2005 7 8 717 722 2-s2.0-33644667332 10.1593/neo.05277
43. Jin M., Komohara Y., Shichijo S., Harada M., Yamanaka R., Miyamoto S., Nikawa J., Itoh K., Yamada A., Identification of EphB6 variant-derived epitope peptides recognized by cytotoxic T-lymphocytes from HLA-A24+ malignant glioma patients. Oncology Reports 2008 19 5 1277 1283 2-s2.0-47549091383
44. Liu G., Yu J. S., Zeng G., Yin D., Xie D., Black K. L., Ying H., AIM-2: a novel tumor antigen is expressed and presented by human glioma cells. Journal of Immunotherapy 2004 27 3 220 226 2-s2.0-4344706290 (Pubitemid 39118086)
45. Schmitz M., Wehner R., Stevanovic S., Kiessling A., Rieger M. A., Temme A., Bachmann M., Rieber E. P., Weigle B., Identification of a naturally processed T cell epitope derived from the glioma-associated protein SOX11. Cancer Letters 2007 245 1-2 331 336 2-s2.0-33845646732 10.1016/j.canlet.2006.01. 014 (Pubitemid 44959365)
46. Cho H.-I., Kim E.-K., Park S.-Y., Lee S. K., Hong Y.-K., Kim T.-G., Enhanced induction of anti-tumor immunity in human and mouse by dendritic cells pulsed with recombinant TAT fused human survivin protein. Cancer Letters 2007 258 2 189 198 2-s2.0-36048950675 10.1016/j.canlet.2007.08.023 (Pubitemid 350101016)
47. Komata T., Kanzawa T., Kondo Y., Kondo S., Telomerase as a therapeutic target for malignant gliomas. Oncogene 2002 21 4 656 663 2-s2.0-0037148280 10.1038/sj/onc/1205072 (Pubitemid 34146268)
48. Jian G. Z., Eguchi J., Kruse C. A., Gomez G. G., Fakhrai H., Schroter S., Ma W., Hoa N., Minev B., Delgado C., Wepsic H. T., Okada H., Jadus M. R., Antigenic profiling of glioma cells to generate allogeneic vaccines or dendritic cell-based therapeutics. Clinical Cancer Research 2007 13 2, part 1 566 575 2-s2.0-33846886376 10.1158/1078-0432.CCR-06-1576 (Pubitemid 46225363)
49. Harada M., Ishihara Y., Itoh K., Yamanaka R., Kinesin superfamily protein-derived peptides with the ability to induce glioma-reactive cytotoxic T lymphocytes in human leukocyte antigen-A24 + glioma patients. Oncology Reports 2007 17 3 629 636 2-s2.0-34247854935
50. Mahaley M. S. Jr., Bigner D. D., Dudka L. F., Wilds P. R., Williams D. H., Bouldin T. W., Whitaker J. N., Bynum J. M., Immunobiology of primary intracranial tumors. Part 7: active immunization of patients with anaplastic human glioma cells: a pilot study. Journal of Neurosurgery 1983 59 2 201 207 2-s2.0-0020507444 (Pubitemid 13029196)
51. Kong S., Sengupta S., Tyler B., Bais A. J., Ma Q., Doucette S., Zhou J., Sahin A., Carter B. S., Brem H., Junghans R. P., Sampath P., Suppression of human glioma xenografts with second-generation IL13R-specific chimeric antigen receptor-modified T cells. Clinical Cancer Research 2012 18 21 5949 5960 2-s2.0-84868576774 10.1158/1078-0432.CCR-12-0319
52. Hussain S. F., Yang D., Suki D., Aldape K., Grimm E., Heimberger A. B., The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses. Neuro-Oncology 2006 8 3 261 279 2-s2.0-33748532939 10.1215/15228517-2006-008 (Pubitemid 46542651)
53. Holladay F. P., Autologous tumor cell vaccination combined with adoptive cellular immunotherapy in patients with grade III/IV astrocytoma. Journal of Neuro-Oncology 1996 27 2 179 189 2-s2.0-0030034580 (Pubitemid 26052654)
54. Platten M., Kretz A., Naumann U., Aulwurm S., Egashira K., Isenmann S., Weller M., Monocyte chemoattractant protein-1 increases microglial infiltration and aggressiveness of gliomas. Annals of Neurology 2003 54 3 388 392 2-s2.0-0041835842 10.1002/ana.10679 (Pubitemid 37072043)
55. Okada M., Saio M., Kito Y., Ohe N., Yano H., Yoshimura S., Iwama T., Takami T., Tumor-associated macrophage/microglia infiltration in human gliomas is correlated with MCP-3, but not MCP-1. International Journal of Oncology 2009 34 6 1621 1627 2-s2.0-67649448823 10.3892/ijo-00000292
56. Quattrocchi K. B., Miller C. H., Cush S., Bernard S. A., Dull S. T., Smith M., Gudeman S., Varia M. A., Pilot study of local autologous tumor infiltrating lymphocytes for the treatment of recurrent malignant gliomas. Journal of Neuro-Oncology 1999 45 2 141 157 2-s2.0-0033506158 10.1023/A:1006293606710 (Pubitemid 30197728)
57. Kitahara T., Watanabe O., Yamaura A., Makino H., Watanabe T., Suzuki G., Okumura K., Establishment of interleukin 2 dependent cytotoxic T lymphocyte cell line specific for autologous brain tumor and its intracranial administration for therapy of the tumor. Journal of Neuro-Oncology 1987 4 4 329 336 2-s2.0-0023148950 10.1007/BF00195603 (Pubitemid 17037579)
58. Tsuboi K., Saijo K., Ishikawa E., Tsurushima H., Takano S., Morishita Y., Ohno T., Effects of local injection of ex vivo expanded autologous tumor-specific T lymphocytes in cases with recurrent malignant gliomas. Clinical Cancer Research 2003 9 9 3294 3302 2-s2.0-0041833713 (Pubitemid 37082723)
59. Kruse C. A., Cepeda L., Owens B., Johnson S. D., Stears J., Lillehei K. O., Treatment of recurrent glioma with intracavitary alloreactive cytotoxic T lymphocytes and interleukin-2. Cancer Immunology Immunotherapy 1997 45 2 77 87 2-s2.0-0030694252 10.1007/s002620050405 (Pubitemid 27497682)
60. Dillman R. O., Duma C. M., Ellis R. A., Cornforth A. N., Schiltz P. M., Sharp S. L., Depriest M. C., Intralesional lymphokine-activated killer cells as adjuvant therapy for primary glioblastoma. Journal of Immunotherapy 2009 32 9 914 919 2-s2.0-70350532587 10.1097/CJI.0b013e3181b2910f
61. Dillman R. O., Duma C. M., Schiltz P. M., DePriest C., Ellis R. A., Okamoto K., Beutel L. D., De Leon C., Chico S., Intracavitary placement of autologous lymphokine-activated killer (LAK) cells after resection of recurrent glioblastoma. Journal of Immunotherapy 2004 27 5 398 404 2-s2.0-4344689067 (Pubitemid 39121929)
62. Sankhla S. K., Nadkarni J. S., Bhagwati S. N., Adoptive immunotherapy using lymphokine-activated killer (LAK) cells and interleukin-2 for recurrent malignant primary brain tumors. Journal of Neuro-Oncology 1996 27 2 133 140 2-s2.0-0030065695
63. Hayes R. L., Koslow M., Hiesiger E. M., Improved long term survival after intracavitary interleukin-2 and lymphokine-activated killer cells for adults with recurrent malignant glioma. Cancer 1995 76 5 840 852
64. Lillehei K. O., Mitchell D. H., Johnson S. D., McCleary E. L., Kruse C. A., Long-term follow-up of patients with recurrent malignant gliomas treated with adjuvant adoptive immunotherapy. Neurosurgery 1991 28 1 16 23 2-s2.0-0025974603
65. Barba D., Saris S. C., Holder C., Rosenberg S. A., Oldfield E. H., Intratumoral LAK cell and interleukin-2 therapy of human gliomas. Journal of Neurosurgery 1989 70 2 175 182 2-s2.0-0024510754 (Pubitemid 19051711)
66. Merchant R. E., Merchant L. H., Cook S. H. S., McVicar D. W., Young H. F., Mahaley M. S. Jr., Intralesional infusion of lymphokine-activated killer (LAK) cells and recombinant Interleukin-2 (rIL-2) for the treatment of patients with malignant brain tumor. Neurosurgery 1988 23 6 725 732 2-s2.0-0024210594 (Pubitemid 19018774)
67. Yoshida S., Tanaka R., Takai N., Ono K., Local administration of autologous lymphokine-activated killer cells and recombinant interleukin 2 to patients with malignant brain tumors. Cancer Research 1988 48 17 5011 5016 2-s2.0-0023758637
68. Merchant R. E., Grant A. J., Merchant L. H., Young H. F., Adoptive immunotherapy for recurrent glioblastoma multiforme using lymphokine activated killer cells and recombinant interleukin-2. Cancer 1988 62 4 665 671 2-s2.0-0023813406
69. Jacobs S. K., Wilson D. J., Kornblith P. L., Grimm E. A., Interleukin-2 or autologous lymphokine-activated killer cell treatment of malignant glioma: phase I trial. Cancer Research 1986 46 4, part 2 2101 2104 2-s2.0-0022641036 (Pubitemid 16117915)
70. Blancher A., Roubinet F., Grancher A. S., Tremoulet M., Bonate A., Delisle M.-B., Calot J.-P., Pourreau C., Franks C., Ducos J., Rascol A., Clanet M., Local immunotherapy of recurrent glioblastoma multiforme by intracerebral perfusion of interleukin-2 and LAK cells. European Cytokine Network 1993 4 5 331 341 2-s2.0-0027139196 (Pubitemid 24001545)
71. Law T. M., Motzer R. J., Mazumdar M., Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma. Cancer 1995 76 5 824 832
72. Bonneville M., Scotet E., Human V γ 9V δ 2 T cells: promising new leads for immunotherapy of infections and tumors. Current Opinion in Immunology 2006 18 5 539 546 2-s2.0-33748131230 10.1016/j.coi.2006.07.002 (Pubitemid 44311448)
73. Borghaei H., Smith M. R., Campbell K. S., Immunotherapy of cancer. European Journal of Pharmacology 2009 625 1-3 41 54 2-s2.0-71749114348 10.1016/j.ejphar.2009.09.067
74. Srivastava S., Lundqvist A., Childs R. W., Natural killer cell immunotherapy for cancer: a new hope. Cytotherapy 2008 10 8 775 783 2-s2.0-57949099850 10.1080/14653240802648181
75. Vivier E., Tomasello E., Baratin M., Walzer T., Ugolini S., Functions of natural killer cells. Nature Immunology 2008 9 5 503 510 2-s2.0-42449151214 10.1038/ni1582 (Pubitemid 351560519)
76. Castriconi R., Daga A., Dondero A., Zona G., Poliani P. L., Melotti A., Griffero F., Marubbi D., Spaziante R., Bellora F., Moretta L., Moretta A., Corte G., Bottino C., NK cells recognize and kill human glioblastoma cells with stem cell-like properties. The Journal of Immunology 2009 182 6 3530 3539 2-s2.0-65449177238 10.4049/jimmunol.0802845
77. Alizadeh D., Zhang L., Brown C. E., Farrukh O., Jensen M. C., Badie B., Induction of anti-glioma natural killer cell response following multiple low-dose intracerebral CpG therapy. Clinical Cancer Research 2010 16 13 3399 3408 2-s2.0-77954232249 10.1158/1078-0432.CCR-09-3087
78. Ishikawa E., Tsuboi K., Takano S., Uchimura E., Nose T., Ohno T., Intratumoral injection of IL-2-activated NK cells enhances the antitumor effect of intradermally injected paraformaldehyde-fixed tumor vaccine in a rat intracranial brain tumor model. Cancer Science 2004 95 1 98 103 2-s2.0-1142299538 10.1111/j.1349-7006.2004.tb03177.x (Pubitemid 38208414)
79. Wang P., Yu J.-P., Gao S.-Y., An X.-M., Ren X.-B., Wang X.-G., Li W.-L., Experimental study on the treatment of intracerebral glioma xenograft with human cytokine-induced killer cells. Cellular Immunology 2008 253 1-2 59 65 2-s2.0-51449090688 10.1016/j.cellimm.2008.04.014
80. Ishikawa E., Tsuboi K., Saijo K., Harada H., Takano S., Nose T., Ohno T., Autologous natural killer cell therapy for human recurrent malignant glioma. Anticancer Research 2004 24 3 B 1861 1871 2-s2.0-3242720680 (Pubitemid 38954600)
81. Pellegatta S., Eoli M., Frigerio S., The natural killer cell response and tumor debulking are associated with prolonged survival in recurrent glioblastoma patients receiving dendritic cells loaded with autologous tumor lysates. Oncoimmunology 2013 2 3 e23401
82. Moretta L., Bottino C., Pende D., Castriconi R., Mingari M. C., Moretta A., Surface NK receptors and their ligands on tumor cells. Seminars in Immunology 2006 18 3 151 158 2-s2.0-33744539802 10.1016/j.smim.2006.03.002 (Pubitemid 43817561)
83. Bakker A. B. H., Phillips J. H., Figdor C. G., Lanier L. L., Killer cell inhibitory receptors for MHC class I molecules regulate lysis of melanoma cells mediated by NK cells, γ δ T cells, and antigen- specific CTL. The Journal of Immunology 1998 160 11 5239 5245 2-s2.0-0032101973 (Pubitemid 28267808)
84. Fujisaki H., Kakuda H., Shimasaki N., Imai C., Ma J., Lockey T., Eldridge P., Leung W. H., Campana D., Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. Cancer Research 2009 69 9 4010 4017 2-s2.0-65949111530 10.1158/0008-5472.CAN-08-3712
85. Cheng M., Chen Y., Xiao W., Sun R., Tian Z., NK cell-based immunotherapy for malignant diseases. Cellular and Molecular Immunology 2013 10 3 230 252 2-s2.0-84877602763 10.1038/cmi.2013.10
86. Pegram H. J., Kershaw M. H., Darcy P. K., Genetic modification of natural killer cells for adoptive cellular immunotherapy. Immunotherapy 2009 1 4 623 630 2-s2.0-77953380756 10.2217/IMT.09.36
87. Nagashima S., Mailliard R., Kashii Y., Reichert T. E., Herberman R. B., Robbins P., Whiteside T. L., Stable transduction of the interleukin-2 gene into human natural killer cell lines and their phenotypic and functional characterization in vitro and in vivo. Blood 1998 91 10 3850 3861 2-s2.0-0032525193 (Pubitemid 28225754)
88. Goding S. R., Yang Q., Knudsen K. B., Potter D. M., Basse P. H., Cytokine gene therapy using adenovirally transduced, tumor-seeking activated natural killer cells. Human Gene Therapy 2007 18 8 701 711 2-s2.0-34548477012 10.1089/hum.2007.052 (Pubitemid 47378067)
89. Vujanovic N. L., Yasumura S., Hirabayashi H., Lin W.-C., Watkins S., Herberman R. B., Whiteside T. L., Antitumor activities of subsets of human IL-2-activated natural killer cells in solid tissues. The Journal of Immunology 1995 154 1 281 289 2-s2.0-0028815217
90. Miller J. S., Tessmer-Tuck J., Blake N., Lund J., Scott A., Blazar B. R., Orchard P. J., Endogenous IL-2 production by natural killer cells maintains cytotoxic and proliferative capacity following retroviral-mediated gene transfer. Experimental Hematology 1997 25 11 1140 1148 2-s2.0-0030818211 (Pubitemid 27444675)
91. Zhang J., Sun R., Wei H., Zhang J., Tian Z., Characterization of interleukin-15 gene-modified human natural killer cells: implications for adoptive cellular immunotherapy. Haematologica 2004 89 3 338 347 2-s2.0-2942755603 (Pubitemid 38788420)
92. Sahm C., Schönfeld K., Wels W. S., Expression of IL-15 in NK cells results in rapid enrichment and selective cytotoxicity of gene-modiWed eVectors that carry a tumor-speciWc antigen receptor. Cancer Immunology, Immunotherapy 2012 61 9 1451 1461 2-s2.0-84866541747 10.1007/s00262-012-1212-x
93. Jiang W., Zhang J., Tian Z., Functional characterization of interleukin-15 gene transduction into the human natural killer cell line NKL. Cytotherapy 2008 10 3 265 274 2-s2.0-42449139629 10.1080/14653240801965156 (Pubitemid 351566528)
94. Zhang J., Sun R., Wei H., Zhang J., Tian Z., Characterization of stem cell factor gene-modified human natural killer cell line, NK-92 cells: implication in NK cell-based adoptive cellular immunotherapy. Oncology Reports 2004 11 5 1097 1106 2-s2.0-12944260838
95. Demirtzoglou F. J., Papadopoulos S., Zografos G., Cytolytic and cytotoxic activity of a human natural killer cell line genetically modified to specifically recognize HER-2/neu overexpressing tumor cells. Immunopharmacology and Immunotoxicology 2006 28 4 571 590 2-s2.0-33845908470 10.1080/ 08923970601066971 (Pubitemid 46026362)
96. Schirrmann T., Pecher G., Human natural killer cell line modified with a chimeric immunoglobulin T-cell receptor gene leads to tumor growth inhibition in vivo. Cancer Gene Therapy 2002 9 4 390 398 2-s2.0-0036221688 10.1038/sj.cgt.7700453 (Pubitemid 34289458)
97. Schirrmann T., Pecher G., Specific targeting of CD33+ leukemia cells by a natural killer cell line modified with a chimeric receptor. Leukemia Research 2005 29 3 301 306 2-s2.0-12344276425 10.1016/j.leukres.2004.07.005 (Pubitemid 40127057)
98. Bronte V., Wang M., Overwijk W. W., Surman D. R., Pericle F., Rosenberg S. A., Restifo N. P., Apoptotic death of CD8+ T lymphocytes after immunization: induction of a suppressive population of Mac-1+/Gr-1+ cells. The Journal of Immunology 1998 161 10 5313 5320 2-s2.0-0032533478 (Pubitemid 28519091)
99. Bronte V., Apolloni E., Cabrelle A., Ronca R., Serafini P., Zamboni P., Restifo N. P., Zanovello P., Identification of a CD11b+/Gr-1+/CD31+ myeloid progenitor capable of activating or suppressing CD8+ T cells. Blood 2000 96 12 3838 3846 2-s2.0-0034551670
100. Lindau D., Gielen P., Kroesen M., Wesseling P., Adema G. J., The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells. Immunology 2013 138 2 105 115 2-s2.0-84872559040 10.1111/imm.12036
101. Zhang B., Jia H., Liu J., Yang Z., Jiang T., Tang K., Li D., Huang C., Ma J., Shen G.-X., Ye D., Huang B., Depletion of regulatory T cells facilitates growth of established tumors: a mechanism involving the regulation of myeloid-derived suppressor cells by lipoxin A4. The Journal of Immunology 2010 185 12 7199 7206 2-s2.0-78650642294 10.4049/jimmunol.1001876
102. Fujimura T., Kambayashi Y., Aiba S., Crosstalk between regulatory T cells (Tregs) and myeloid derived suppressor cells (MDSCs) during melanoma growth. Oncoimmunology 2012 1 8 1433 1434
103. Raychaudhuri B., Ireland P. R. J., Ko J., Rini B., Borden E. C., Garcia J., Vogelbaum M. A., Finke J., Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma. Neuro-Oncology 2011 13 6 591 599 2-s2.0-79960003585 10.1093/neuonc/nor042
104. Rodrigues J. C., Gonzalez G. C., Zhang L., Ibrahim G., Kelly J. J., Gustafson M. P., Lin Y., Dietz A. B., Forsyth P. A., Yong V. W., Parney I. F., Normal human monocytes exposed to glioma cells acquire myeloid-derived suppressor cell-like properties. Neuro-Oncology 2010 12 4 351 365 2-s2.0-77954641353 10.1093/neuonc/nop023
105. Fujita M., Kohanbash G., Fellows-Mayle W., Hamilton R. L., Komohara Y., Decker S. A., Ohlfest J. R., Okada H., COX-2 blockade suppresses gliomagenesis by inhibiting myeloid-derived suppressor cells. Cancer Research 2011 71 7 2664 2674 2-s2.0-79953324535 10.1158/0008-5472.CAN-10-3055
106. Zhu X., Fujita M., Snyder L. A., Okada H., Systemic delivery of neutralizing antibody targeting CCL2 for glioma therapy. Journal of Neuro-Oncology 2011 104 1 83 92 2-s2.0-80052746486 10.1007/s11060-010-0473-5
107. Sonabend A. M., Rolle C. E., Lesniak M. S., The role of regulatory T cells in malignant glioma. Anticancer Research 2008 28 2 1143 1150 2-s2.0-42549126264 (Pubitemid 351578852)
108. Smyth M. J., Teng M. W. L., Swann J., Kyparissoudis K., Godfrey D. I., Hayakawa Y., CD4+CD25+ T regulatory cells suppress NK cell-mediated immunotherapy of cancer. The Journal of Immunology 2006 176 3 1582 1587 2-s2.0-31144468294 (Pubitemid 43134302)
109. Zhou H., Chen L., You Y., Zou L., Zou P., Foxp3-transduced polyclonal regulatory T cells suppress NK cell functions in a TGF- β dependent manner. Autoimmunity 2010 43 4 299 307 2-s2.0-77952488664 10.3109/08916930903405875
110. Lamb L. S. Jr., γ δ T cells as immune effectors against high-grade gliomas. Immunologic Research 2009 45 1 85 95 2-s2.0-70349593630 10.1007/s12026-009-8114-9
111. Yamaguchi T., Fujimiya Y., Suzuki Y., Katakura R., Ebina T., A simple method for the propagation and purification of γ δ T cells from the peripheral blood of glioblastoma patients using solid-phase anti-CD3 antibody and soluble IL-2. Journal of Immunological Methods 1997 205 1 19 28 2-s2.0-0030744092 10.1016/S0022-1759(97)00062-8 (Pubitemid 27297830)
112. Fujimiya Y., Suzuki Y., Katakura R., Miyagi T., Yamaguchi T., Yoshimoto T., Ebina T., In vitro interleukin 12 activation of peripheral blood CD3+ CD56+ and CD3+ CD56- γ δ T cells from glioblastoma patients. Clinical Cancer Research 1997 3 4 633 643 2-s2.0-0031005628 (Pubitemid 27211844)
113. Yamaguchi T., Suzuki Y., Katakura R., Ebina T., Yokoyama J., Fujimiya Y., Interleukin-15 effectively potentiates the in vitro tumor-specific activity and proliferation of peripheral blood γ δ T cells isolated from glioblastoma patients. Cancer Immunology Immunotherapy 1998 47 2 97 103 2-s2.0-0031713495 10.1007/s002620050509 (Pubitemid 28443560)
114. Bryant N. L., Gillespie G. Y., Lopez R. D., Markert J. M., Cloud G. A., Langford C. P., Arnouk H., Su Y., Haines H. L., Suarez-Cuervo C., Lamb L. S. Jr., Preclinical evaluation of ex vivo expanded/activated γ δ T cells for immunotherapy of glioblastoma multiforme. Journal of Neuro-Oncology 2011 101 2 179 188 2-s2.0-78651291782 10.1007/s11060-010-0245-2
115. Bryant N. L., Suarez-Cuervo C., Gillespie G. Y., Markert J. M., Nabors L. B., Meleth S., Lopez R. D., Lamb L. S. Jr., Characterization and immunotherapeutic potential of γ δ T-cells in patients with glioblastoma. Neuro-Oncology 2009 11 4 357 367 2-s2.0-68949103795 10.1215/15228517-2008-111
116. Lamb L. S. Jr., Bowersock J., Dasgupta A., Gillespie G. Y., Su Y., Johnson A., Spencer H. T., Engineered drug resistant γ δ T cells kill glioblastoma cell lines during a chemotherapy challenge: a strategy for combining chemo- and immunotherapy. PLoS ONE 2013 8 1 2-s2.0-84872260923 10.1371/journal.pone.0051805 e51805
117. Schlitz P. M., Beutel L. D., Nayak S. K., Dillman R. O., Characterization of tumor-infiltrating lymphocytes derived from human tumors for use as adoptive immunotherapy of cancer. Journal of Immunotherapy 1997 20 5 377 386 2-s2.0-0345368069 (Pubitemid 28011534)
118. Dudley M. E., Wunderlich J. R., Robbins P. F., Yang J. C., Hwu P., Schwartzentruber D. J., Topalian S. L., Sherry R., Restifo N. P., Hubicki A. M., Robinson M. R., Raffeld M., Duray P., Seipp C. A., Rogers-Freezer L., Morton K. E., Mavroukakis S. A., White D. E., Rosenberg S. A., Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002 298 5594 850 854 2-s2.0-0037174674 10.1126/science.1076514 (Pubitemid 35231542)
119. Dudley M. E., Yang J. C., Sherry R., Hughes M. S., Royal R., Kammula U., Robbins P. F., Huang J., Citrin D. E., Leitman S. F., Wunderlich J., Restifo N. P., Thomasian A., Downey S. G., Smith F. O., Klapper J., Morton K., Laurencot C., White D. E., Rosenberg S. A., Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. Journal of Clinical Oncology 2008 26 32 5233 5239 2-s2.0-55949125601 10.1200/JCO.2008.16.5449
120. Balch C. M., Riley L. B., Bae Y. J., Salmeron M. A., Platsoucas C. D., Von Eschenbach A., Itoh K., Patterns of human tumor-infiltrating lymphocytes in 120 human cancers. Archives of Surgery 1990 125 2 200 205 2-s2.0-0025012845 (Pubitemid 20060644)
121. Tsurushima H., Liu S. Q., Tuboi K., Matsumura A., Yoshii Y., Nose T., Saijo K., Ohno T., Reduction of end-stage malignant glioma by injection with autologous cytotoxic T lymphocytes. Japanese Journal of Cancer Research 1999 90 5 536 545 2-s2.0-0032999584 (Pubitemid 29267708)
122. Plautz G. E., Miller D. W., Barnett G. H., Stevens G. H. J., Maffett S., Kim J., Cohen P. A., Shu S., T cell adoptive immunotherapy of newly diagnosed gliomas. Clinical Cancer Research 2000 6 6 2209 2218 2-s2.0-0034044202 (Pubitemid 30399186)
123. Plautz G. E., Barnett G. H., Miller D. W., Cohen B. H., Prayson R. A., Krauss J. C., Luciano M., Kangisser D. B., Shu S., Systemic T cell adoptive immunotherapy of malignant gliomas. Journal of Neurosurgery 1998 89 1 42 51 2-s2.0-0031832638 (Pubitemid 28285921)
124. Wood G. W., Holladay F. P., Turner T., Wang Y.-Y., Chiga M., A pilot study of autologous cancer cell vaccination and cellular immunotherapy using anti-CD3 stimulated lymphocytes in patients with recurrent grade III/IV astrocytoma. Journal of Neuro-Oncology 2000 48 2 113 120 2-s2.0-0033781501 10.1023/A:1006456421177
125. Sloan A. E., Dansey R., Zamorano L., Barger G., Hamm C., Diaz F., Baynes R., Wood G., Adoptive immunotherapy in patients with recurrent malignant glioma: preliminary results of using autologous whole-tumor vaccine plus granulocyte-macrophage colony-stimulating factor and adoptive transfer of anti-CD3-activated lymphocytes. Neurosurgical Focus 2000 9 6 e9 2-s2.0-33746816721
126. Ostrand-Rosenberg S., CD4+ T lymphocytes: a critical component of antitumor immunity. Cancer Investigation 2005 23 5 413 419 2-s2.0-24944476490 10.1081/CNV-67428 (Pubitemid 41324359)
127. Pardoll D. M., Topalian S. L., The role of CD4+ T cell responses in antitumor immunity. Current Opinion in Immunology 1998 10 5 588 594 2-s2.0-0031782910 10.1016/S0952-7915(98)80228-8 (Pubitemid 28479193)
128. Hunder N. N., Wallen H., Cao J., Hendricks D. W., Reilly J. Z., Rodmyre R., Jungbluth A., Gnjatic S., Thompson J. A., Yee C., Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. The New England Journal of Medicine 2008 358 25 2698 2703 2-s2.0-45549099784 10.1056/NEJMoa0800251 (Pubitemid 351860862)
129. Depontieu F. R., Qian J., Zarling A. L., McMiller T. L., Salay T. M., Norris A., Michelle English A., Shabanowitz J., Engelhard V. H., Hunt D. F., Topalian S. L., Identification of tumor-associated, MHC class II-restricted phosphopeptides as targets for immunotherapy. Proceedings of the National Academy of Sciences of the United States of America 2009 106 29 12073 12078 2-s2.0-67749145750 10.1073/pnas.0903852106
130. Perez-Diez A., Joncker N. T., Choi K., Chan W. F. N., Anderson C. C., Lantz O., Matzinger P., CD4 cells can be more efficient at tumor rejection than CD8 cells. Blood 2007 109 12 5346 5354 2-s2.0-34249990107 10.1182/blood-2006-10- 051318 (Pubitemid 46890556)
131. Ossendorp F., Mengedé E., Camps M., Filius R., Melief C. J. M., Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. The Journal of Experimental Medicine 1998 187 5 693 702 2-s2.0-0032473562 10.1084/jem.187.5.693 (Pubitemid 28115185)
132. Xie Y., Akpinarli A., Maris C., Hipkiss E. L., Lane M., Kwon E.-K. M., Muranski P., Restifo N. P., Antony P. A., Naive tumor-specific CD4+ T cells differentiated in vivo eradicate established melanoma. The Journal of Experimental Medicine 2010 207 3 651 667 2-s2.0-77949530108 10.1084/jem.20091921
133. Quezada S. A., Simpson T. R., Peggs K. S., Merghoub T., Vider J., Fan X., Blasberg R., Yagita H., Muranski P., Antony P. A., Restifo N. P., Allison J. P., Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. The Journal of Experimental Medicine 2010 207 3 637 650 2-s2.0-77949522803 10.1084/jem.20091918
134. Xiang J., Moyana T., Cytotoxic CD4+ T cells associated with the expression of major histocompatibility complex class II antigen of mouse myeloma cells secreting interferon- γ are cytolytic in vitro and tumoricidal in vivo. Cancer Gene Therapy 1998 5 5 313 320 2-s2.0-0032150753 (Pubitemid 128640018)
135. Hodi F. S., Fisher D. E., Adoptive transfer of antigen-specific CD4+ T cells in the treatment of metastatic melanoma. Nature Clinical Practice Oncology 2008 5 12 696 697 2-s2.0-57049143114 10.1038/ncponc1259
136. Dembic Z., Haas W., Weiss S., McCubrey J., Kiefer H., von Boehmer H., Steinmetz M., Transfer of specificity by murine and β T-cell receptor genes. Nature 1986 320 6059 232 238 2-s2.0-0022538117 (Pubitemid 16040238)
137. Stephan M. T., Ponomarev V., Brentjens R. J., Chang A. H., Dobrenkov K. V., Heller G., Sadelain M., T cell-encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection. Nature Medicine 2007 13 12 1440 1449 2-s2.0-36849021712 10.1038/nm1676 (Pubitemid 350224246)
138. Liu K., Rosenberg S. A., Transduction of an IL-2 gene into human melanoma-reactive lymphocytes results in their continued growth in the absence of exogenous IL-2 and maintenance of specific antitumor activity. The Journal of Immunology 2001 167 11 6356 6365 2-s2.0-0035575701 (Pubitemid 33081567)
139. Hsu C., Hughes M. S., Zheng Z., Bray R. B., Rosenberg S. A., Morgan R. A., Primary human T lymphocytes engineered with a codon-optimized IL-15 gene resist cytokine withdrawal-induced apoptosis and persist long-term in the absence of exogenous cytokine. The Journal of Immunology 2005 175 11 7226 7234 2-s2.0-28244460980 (Pubitemid 41713417)
140. Vera J. F., Hoyos V., Savoldo B., Quintarelli C., Giordano Attianese G. M. P., Leen A. M., Liu H., Foster A. E., Heslop H. E., Rooney C. M., Brenner M. K., Dotti G., Genetic manipulation of tumor-specific cytotoxic T lymphocytes to restore responsiveness to IL-7. Molecular Therapy 2009 17 5 880 888 2-s2.0-67349252824 10.1038/mt.2009.34
141. Kerkar S. P., Muranski P., Kaiser A., Boni A., Sanchez-Perez L., Yu Z., Palmer D. C., Reger R. N., Borman Z. A., Zhang L., Morgan R. A., Gattinoni L., Rosenberg S. A., Trinchieri G., Restifo N. P., Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts. Cancer Research 2010 70 17 6725 6734 2-s2.0-77956280888 10.1158/0008-5472.CAN- 10-0735
142. Kalbasi A., Shrimali R. K., Chinnasamy D., Rosenberg S. A., Prevention of interleukin-2 withdrawal-induced apoptosis in lymphocytes retrovirally cotransduced with genes encoding an antitumor t-cell receptor and an antiapoptotic protein. Journal of Immunotherapy 2010 33 7 672 683 2-s2.0-77955177074 10.1097/CJI.0b013e3181e475cd
143. Eaton D., Gilham D. E., O'Neill A., Hawkins R. E., Retroviral transduction of human peripheral blood lymphocytes with bcl-XL promotes in vitro lymphocyte survival in pro-apoptotic conditions. Gene Therapy 2002 9 8 527 535 2-s2.0-0036242057 10.1038/sj/gt/3301685 (Pubitemid 34449773)
144. Charo J., Finkelstein S. E., Grewal N., Restifo N. P., Robbins P. F., Rosenberg S. A., Bcl-2 overexpression enhances tumor-specific T-cell survival. Cancer Research 2005 65 5 2001 2008 2-s2.0-16444381331 10.1158/0008-5472.CAN-04- 2006 (Pubitemid 40478630)
145. Mizukoshi E., Nakamoto Y., Marukawa Y., Arai K., Yamashita T., Tsuji H., Kuzushima K., Takiguchi M., Kaneko S., Cytotoxic T cell responses to human telomerase reverse transcriptase in patients with hepatocellular carcinoma. Hepatology 2006 43 6 1284 1294 2-s2.0-33745527109 10.1002/hep.21203 (Pubitemid 43980107)
146. Shen X., Zhou J., Hathcock K. S., Robbins P., Powell D. J. Jr., Rosenberg S. A., Hodes R. J., Persistence of tumor infiltrating lymphocytes in adoptive immunotherapy correlates with telomere length. Journal of Immunotherapy 2007 30 1 123 129 2-s2.0-33846028221 10.1097/01.cji.0000211321.07654.b8 (Pubitemid 46052211)
147. Migliaccio M., Amacker M., Just T., Reichenbach P., Valmori D., Cerottini J.-C., Romero P., Nabholz M., Ectopic human telomerase catalytic subunit expression maintains telomere length but is not sufficient for CD8+ T lymphocyte immortalization. The Journal of Immunology 2000 165 9 4978 4984 2-s2.0-0034326634
148. Hooijberg E., Ruizendaal J. J., Snijders P. J. F., Kueter E. W. M., Walboomers J. M. M., Spits H., Immortalization of human CD8+ T cell clones by ectopic expression of telomerase reverse transcriptase. The Journal of Immunology 2000 165 8 4239 4245 2-s2.0-0034667771
149. Sapoznik S., Ortenberg R., Galore-Haskel G., Kozlovski S., Levy D., Avivi C., Barshack I., Cohen C. J., Besser M. J., Schachter J., Markel G., CXCR1 as a novel target for directing reactive T cells toward melanoma: implications for adoptive cell transfer immunotherapy. Cancer Immunology, Immunotherapy 2012 61 10 1833 1847 2-s2.0-84867577248 10.1007/s00262-012-1245-1
150. Peng W., Ye Y., Rabinovich B. A., Liu C., Lou Y., Zhang M., Whittington M., Yang Y., Overwijk W. W., Lizée G., Hwu P., Transduction of tumor-specific T cells with CXCR2 chemokine receptor improves migration to tumor and antitumor immune responses. Clinical Cancer Research 2010 16 22 5458 5468 2-s2.0-78349255049 10.1158/1078-0432.CCR-10-0712
151. Craddock J. A., Lu A., Bear A., Pule M., Brenner M. K., Rooney C. M., Foster A. E., Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b. Journal of Immunotherapy 2010 33 8 780 788 2-s2.0-77958063691 10.1097/CJI.0b013e3181ee6675
152. Kershaw M. H., Hwu P., Wang G., Westwood J. A., Pachynski R. K., Tiffany H. L., Marincola F. M., Wang E., Young H. A., Murphy P. M., Redirecting migration of T cells to chemokine secreted from tumors by genetic modification with CXCR2. Human Gene Therapy 2002 13 16 1971 1980 2-s2.0-0036428790 10.1089/10430340260355374 (Pubitemid 35341038)
153. Wang L., Wen W., Yuan J., Helfand B., Li Y., Shi C., Tian F., Zheng J., Wang F., Chen L., Liang L., Zhou L., Lee C., Chen Z., Guo Y., Wang H., Zhang Q., Qin W., Immunotherapy for human renal cell carcinoma by adoptive transfer of autologous transforming growth factor β -insensitive CD8+ T cells. Clinical Cancer Research 2010 16 1 164 173 2-s2.0-74949117968 10.1158/1078-0432.CCR-09- 1758
154. Zhang Q., Yang X., Pins M., Javonovic B., Kuzel T., Kim S.-J., Van Parijs L., Greenberg N. M., Liu V., Guo Y., Lee C., Adoptive transfer of tumor-reactive transforming growth factor- β -insensitive CD8+ T cells: eradication of autologous mouse prostate cancer. Cancer Research 2005 65 5 1761 1769 2-s2.0-20144387943 10.1158/0008-5472.CAN-04-3169 (Pubitemid 40478602)
155. Bollard C. M., Rössig C., Julia Calonge M., Helen Huls M., Wagner H.-J., Massague J., Brenner M. K., Heslop H. E., Rooney C. M., Adapting a transforming growth factor β -related tumor protection strategy to enhance antitumor immunity. Blood 2002 99 9 3179 3187 2-s2.0-0036566184 10.1182/blood.V99.9.3179 (Pubitemid 34525296)
156. Foster A. E., Dotti G., Lu A., Khalil M., Brenner M. K., Heslop H. E., Rooney C. M., Bollard C. M., Antitumor activity of EBV-specific T lymphocytes transduced with a dominant negative TGF- β receptor. Journal of Immunotherapy 2008 31 5 500 505 2-s2.0-55249117972 10.1097/CJI.0b013e318177092b
157. Dotti G., Savoldo B., Pule M., Straathof K. C., Biagi E., Yvon E., Vigouroux S., Brenner M. K., Rooney C. M., Human cytotoxic T lymphocytes with reduced sensitivity to Fas-induced apoptosis. Blood 2005 105 12 4677 4684 2-s2.0-20444425695 10.1182/blood-2004-08-3337 (Pubitemid 40807289)
158. Restifo N. P., Dudley M. E., Rosenberg S. A., Adoptive immunotherapy for cancer: harnessing the T cell response. Nature Reviews Immunology 2012 12 4 269 281 2-s2.0-84858758766 10.1038/nri3191
159. Haynes N. M., Trapani J. A., Teng M. W. L., Jackson J. T., Cerruti L., Jane S. M., Kershaw M. H., Smyth M. J., Darcy P. K., Rejection of syngeneic colon carcinoma by CTLs expressing single-chain antibody receptors codelivering CD28 costimulation. The Journal of Immunology 2002 169 10 5780 5786 2-s2.0-0037111240 (Pubitemid 35291680)
160. Shen C.-J., Yang Y.-X., Han E. Q., Cao N., Wang Y.-F., Wang Y., Zhao Y.-Y., Zhao L.-M., Cui J., Gupta P., Wong A. J., Han S.-Y., Chimeric antigen receptor containing ICOS signaling domain mediates specific and efficient antitumor effect of T cells against EGFRvIII expressing glioma. Journal of Hematology and Oncology 2013 6 1, article 33 2-s2.0-84877116624 10.1186/1756-8722-6-33
161. Lucas K. G., Bao L., Bruggeman R., Dunham K., Specht C., The detection of CMV pp65 and IE1 in glioblastoma multiforme. Journal of Neuro-Oncology 2011 103 2 231 238 2-s2.0-79959834313 10.1007/s11060-010-0383-6
162. Dziurzynski K., Wei J., Qiao W., Hatiboglu M. A., Kong L.-Y., Wu A., Wang Y., Cahill D., Levine N., Prabhu S., Rao G., Sawaya R., Heimberger A. B., Glioma-associated cytomegalovirus mediates subversion of the monocyte lineage to a tumor propagating phenotype. Clinical Cancer Research 2011 17 14 4642 4649 2-s2.0-79960432578 10.1158/1078-0432.CCR-11-0414
163. Ghazi A., Ashoori A., Hanley P. J., Brawley V. S., Shaffer D. R., Kew Y., Powell S. Z., Grossman R., Grada Z., Scheurer M. E., Hegde M., Leen A. M., Bollard C. M., Rooney C. M., Heslop H. E., Gottschalk S., Ahmed N., Generation of polyclonal CMV-specific T cells for the adoptive immunotherapy of glioblastoma. Journal of Immunotherapy 2012 35 2 159 168 2-s2.0-84856845120 10.1097/CJI.0b013e318247642f
164. Crough T., Beagley L., Smith C., Jones L., Walker D. G., Khanna R., Ex vivo functional analysis, expansion and adoptive transfer of cytomegalovirus-specific T-cells in patients with glioblastoma multiforme. Immunology and Cell Biology 2012 90 9 872 880 2-s2.0-84867744197 10.1038/icb.2012.19
165. Brown C. E., Starr R., Naranjo A., Adoptive transfer of autologous IL13-zetakine+ engineered T cell clones for the treatment of recurrent glioblastoma: lessons from the Clinic. Molecular Therapy 2011 19, supplement 1 S136 S137
166. Sampson J. H., Heimberger A. B., Archer G. E., Aldape K. D., Friedman A. H., Friedman H. S., Gilbert M. R., Herndon J. E. II, McLendon R. E., Mitchell D. A., Reardon D. A., Sawaya R., Schmittling R. J., Shi W., Vredenburgh J. J., Bigner D. D., Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. Journal of Clinical Oncology 2010 28 31 4722 4729 2-s2.0-78149254368 10.1200/JCO.2010.28.6963
167. Morgan R. A., Yang J. C., Kitano M., Dudley M. E., Laurencot C. M., Rosenberg S. A., Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Molecular Therapy 2010 18 4 843 851 2-s2.0-77950475517 10.1038/mt.2010.24
168. Zhang Y., Joe G., Hexner E., Zhu J., Emerson S. G., Host-reactive CD8+ memory stem cells in graft-versus-host disease. Nature Medicine 2005 11 12 1299 1305 2-s2.0-28644437672 10.1038/nm1326 (Pubitemid 41752910)
169. Klebanoff C. A., Gattinoni L., Restifo N. P., Sorting through subsets: which T-cell populations mediate highly effective adoptive immunotherapy? Journal of Immunotherapy 2012 35 9 651 660 2-s2.0-84868255419 10.1097/CJI.0b013e31827806e6
170. Hinrichs C. S., Spolski R., Paulos C. M., Gattinoni L., Kerstann K. W., Palmer D. C., Klebanoff C. A., Rosenberg S. A., Leonard W. J., Restifo N. P., IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy. Blood 2008 111 11 5326 5333 2-s2.0-45449087723 10.1182/blood-2007-09-113050
171. Li Y., Bleakley M., Yee C., IL-21 influences the frequency, phenotype, and affinity of the antigen-specific CD8 T cell response. The Journal of Immunology 2005 175 4 2261 2269 2-s2.0-23444445913 (Pubitemid 41113833)
172. Pouw N., Treffers-Westerlaken E., Mondino A., Lamers C., Debets R., TCR gene-engineered T cell: limited T cell activation and combined use of IL-15 and IL-21 ensure minimal differentiation and maximal antigen-specificity. Molecular Immunology 2010 47 7-8 1411 1420 2-s2.0-77950603634 10.1016/j.molimm.2010.02.022
173. Gattinoni L., Zhong X.-S., Palmer D. C., Ji Y., Hinrichs C. S., Yu Z., Wrzesinski C., Boni A., Cassard L., Garvin L. M., Paulos C. M., Muranski P., Restifo N. P., Wnt signaling arrests effector T cell differentiation and generates CD8 + memory stem cells. Nature Medicine 2009 15 7 808 813 2-s2.0-67650465237 10.1038/nm.1982
174. Muralidharan S., Hanley P. J., Liu E., Chakraborty R., Bollard C., Shpall E., Rooney C., Savoldo B., Rodgers J., Dotti G., Activation of Wnt signaling arrests effector differentiation in human peripheral and cord blood-derived T lymphocytes. The Journal of Immunology 2011 187 10 5221 5232 2-s2.0-81455154955 10.4049/jimmunol.1101585
175. Lugli E., Dominguez M. H., Gattinoni L., Chattopadhyay P. K., Bolton D. L., Song K., Klatt N. R., Brenchley J. M., Vaccari M., Gostick E., Price D. A., Waldmann T. A., Restifo N. P., Franchini G., Roederer M., Superior T memory stem cell persistence supports long-lived T cell memory. The Journal of Clinical Investigation 2013 123 2 594 599 2-s2.0-84873395620 10.1172/JCI66327
176. Klebanoff C. A., Gattinoni L., Torabi-Parizi P., Kerstann K., Cardones A. R., Finkelstein S. E., Palmer D. C., Antony P. A., Hwang S. T., Rosenberg S. A., Waldmann T. A., Restifo N. P., Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. Proceedings of the National Academy of Sciences of the United States of America 2005 102 27 9571 9576 2-s2.0-22144437688 10.1073/pnas.0503726102 (Pubitemid 40981722)
177. Gattinoni L., Lugli E., Ji Y., Pos Z., Paulos C. M., Quigley M. F., Almeida J. R., Gostick E., Yu Z., Carpenito C., Wang E., Douek D. C., Price D. A., June C. H., Marincola F. M., Roederer M., Restifo N. P., A human memory T cell subset with stem cell-like properties. Nature Medicine 2011 17 10 1290 1297 2-s2.0-80053997259 10.1038/nm.2446
178. Tanchot C., Rosado M. M., Agenes F., Freitas A. A., Rocha B., Lymphocyte homeostasis. Seminars in Immunology 1997 9 6 331 337 2-s2.0-0031434613 10.1006/smim.1997.0090 (Pubitemid 28021490)
179. Cobbold M., Khan N., Pourgheysari B., Tauro S., McDonald D., Osman H., Assenmacher M., Billingham L., Steward C., Crawley C., Olavarria E., Goldman J., Chakraverty R., Mahendra P., Craddock C., Moss P. A. H., Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers. The Journal of Experimental Medicine 2005 202 3 379 386 2-s2.0-23744516707 10.1084/jem.20040613 (Pubitemid 41126955)
180. Cho B. K., Rao V. P., Ge Q., Eisen H. N., Chen J., Homeostasis-stimulated proliferation drives naive T cells to differentiate directly into memory T cells. The Journal of Experimental Medicine 2000 192 4 549 556 2-s2.0-0034698828 10.1084/jem.192.4.549 (Pubitemid 30666255)
181. Dummer W., Niethammer A. G., Baccala R., Lawson B. R., Wagner N., Reisfeld R. A., Theofilopoulos A. N., T cell homeostatic proliferation elicits effective antitumor autoimmunity. The Journal of Clinical Investigation 2002 110 2 185 192 2-s2.0-0036076114 10.1172/JCI200215175 (Pubitemid 34787355)
182. Asavaroengchai W., Kotera Y., Mulé J. J., Tumor lysate-pulsed dendritic cells can elicit an effective antitumor immune response during early lymphoid recovery. Proceedings of the National Academy of Sciences of the United States of America 2002 99 2 931 936 2-s2.0-0037154222 10.1073/pnas.022634999 (Pubitemid 34106613)
183. Hu H.-M., Poehlein C. H., Urba W. J., Fox B. A., Development of antitumor immune responses in reconstituted lymphopenic hosts. Cancer Research 2002 62 14 3914 3919 2-s2.0-0037099515 (Pubitemid 34791051)
184. Koike N., Pilon-Thomas S., Mulé J. J., Nonmyeloablative chemotherapy followed by T-cell adoptive transfer and dendritic cell-based vaccination results in rejection of established melanoma. Journal of Immunotherapy 2008 31 4 402 412 2-s2.0-42649085033 10.1097/CJI.0b013e31816cabbb (Pubitemid 351595163)
185. Hong J. J., Rosenberg S. A., Dudley M. E., Yang J. C., White D. E., Butman J. A., Sherry R. M., Successful treatment of melanoma brain metastases with adoptive cell therapy. Clinical Cancer Research 2010 16 19 4892 4898 2-s2.0-77957606517 10.1158/1078-0432.CCR-10-1507
186. Rosenberg S. A., Dudley M. E., Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes. Proceedings of the National Academy of Sciences of the United States of America 2004 101, supplement 2 14639 14645 2-s2.0-5144226237 10.1073/pnas.0405730101 (Pubitemid 39346736)
187. King C., Ilic A., Koelsch K., Sarvetnick N., Homeostatic expansion of T cells during immune insufficiency generates autoimmunity. Cell 2004 117 2 265 277 2-s2.0-1942453326 10.1016/S0092-8674(04)00335-6 (Pubitemid 38496245)
188. Krupica T. Jr., Fry T. J., Mackall C. L., Autoimmunity during lymphopenia: a two-hit model. Clinical Immunology 2006 120 2 121 128 2-s2.0-33746189876 10.1016/j.clim.2006.04.569 (Pubitemid 44088681)
189. Powell D. J. Jr., Dudley M. E., Hogan K. A., Wunderlich J. R., Rosenberg S. A., Adoptive transfer of vaccine-induced peripheral blood mononuclear cells to patients with metastatic melanoma following lymphodepletion. The Journal of Immunology 2006 177 9 6527 6539 2-s2.0-33750343038 (Pubitemid 44628872)
190. Christiansson L., Söderlund S., Svensson E., Mustjoki S., Bengtsson M., Simonsson B., Olsson-Strömberg U., Loskog A. S. I., Increased Level of Myeloid-Derived Suppressor Cells, Programmed Death Receptor Ligand 1/Programmed Death Receptor 1, and Soluble CD25 in Sokal High Risk Chronic Myeloid Leukemia. PLoS ONE 2013 8 1 2-s2.0-84873192230 10.1371/journal.pone.0055818 e55818
191. Wang L., Chang E. W. Y., Wong S., Ong S.-M., Chong D. Q. Y., Ling K. L., Increased myeloid-derived suppressor cells in gastric cancer correlate with cancer stage and plasma S100A8/A9 proinflammatory proteins. The Journal of Immunology 2013 190 2 794 804 2-s2.0-84872172395 10.4049/jimmunol.1202088
192. Ohki S., Shibata M., Gonda K., Machida T., Shimura T., Nakamura I., Ohtake T., Koyama Y., Suzuki S., Ohto H., Takenoshita S., Circulating myeloid-derived suppressor cells are increased and correlate to immune suppression, inflammation and hypoproteinemia in patients with cancer. Oncology Reports 2012 28 2 453 458 2-s2.0-84863484555 10.3892/or.2012.1812
193. Gabrilovich D. I., Nagaraj S., Myeloid-derived suppressor cells as regulators of the immune system. Nature Reviews Immunology 2009 9 3 162 174 2-s2.0-61349100687 10.1038/nri2506
194. Kodumudi K. N., Weber A., Sarnaik A. A., Pilon-Thomas S., Blockade of myeloid-derived suppressor cells after induction of lymphopenia improves adoptive T cell therapy in a murine model of melanoma. The Journal of Immunology 2012 189 11 5147 5154 2-s2.0-84869791457 10.4049/jimmunol.1200274
195. Winstead C. J., Fraser J. M., Khoruts A., Regulatory CD4 +CD25 +Foxp3 + T cells selectively inhibit the spontaneous form of lymphopenia-induced proliferation of naive T cells. The Journal of Immunology 2008 180 11 7305 7317 2-s2.0-47249163695
196. Winstead C. J., Reilly C. S., Moon J. J., Jenkins M. K., Hamilton S. E., Jameson S. C., Way S. S., Khoruts A., CD4+CD25+Foxp3+ regulatory T cells optimize diversity of the conventional T cell repertoire during reconstitution from lymphopenia. The Journal of Immunology 2010 184 9 4749 4760 2-s2.0-77954502214 10.4049/jimmunol.0904076
197. Baba J., Watanabe S., Saida Y., Tanaka T., Miyabayashi T., Koshio J., Ichikawa K., Nozaki K., Koya T., Deguchi K., Tan C., Miura S., Tanaka H., Tanaka J., Kagamu H., Yoshizawa H., Nakata K., Narita I., Depletion of radio-resistant regulatory T cells enhances antitumor immunity during recovery from lymphopenia. Blood 2012 120 12 2417 2427 2-s2.0-84866552661 10.1182/blood-2012- 02-411124
198. Sampson J. H., Schmittling R. J., Archer G. E., Congdon K. L., Nair S. K., Reap E. A., Desjardins A., Friedman A. H., Friedman H. S., Herndon J. E. II, Coan A., McLendon R. E., Reardon D. A., Vredenburgh J. J., Bigner D. D., Mitchell D. A., A pilot study of IL-2R blockade during lymphopenia depletes regulatory T-cells and correlates with enhanced immunity in patients with glioblastoma. PLoS ONE 2012 7 2 2-s2.0-84857547272 10.1371/journal.pone.0031046 e31046
199. Wrzesinski C., Paulos C. M., Gattinoni L., Palmer D. C., Kaiser A., Yu Z., Rosenberg S. A., Restifo N. P., Hematopoietic stem cells promote the expansion and function of adoptively transferred antitumor CD8+ T cells. The Journal of Clinical Investigation 2007 117 2 492 501 2-s2.0-33846787125 10.1172/JCI30414 (Pubitemid 46203978)
200. Paulos C. M., Wrzesinski C., Kaiser A., Hinrichs C. S., Chieppa M., Cassard L., Palmer D. C., Boni A., Muranski P., Yu Z., Gattinoni L., Antony P. A., Rosenberg S. A., Restifo N. P., Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling. The Journal of Clinical Investigation 2007 117 8 2197 2204 2-s2.0-34547686398 10.1172/JCI32205 (Pubitemid 47219564)
201. Wallace A., Kapoor V., Sun J., Mrass P., Weninger W., Heitjan D. F., June C., Kaiser L. R., Ling L. E., Albelda S. M., Transforming growth factor- β receptor blockade augments the effectiveness of adoptive T-cell therapy of established solid cancers. Clinical Cancer Research 2008 14 12 3966 3974 2-s2.0-52449122955 10.1158/1078-0432.CCR-08-0356
202. Wong'S D. H., Inhibiting TGF- β signaling restores immune surveillance in the SMA-560 glioma model. Neuro-Oncology 2007 9 3 259 270 2-s2.0-60849091908 10.1215/15228517-2007-034
203. Uhl M., Aulwurm S., Wischhusen J., Weiler M., Ma J. Y., Almirez R., Mangadu R., Liu Y.-W., Platten M., Herrlinger U., Murphy A., Wong D. H., Wick W., Higgins L. S., Weller M., SD-208, a novel transforming growth factor β receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo. Cancer Research 2004 64 21 7954 7961 2-s2.0-7444226411 10.1158/0008-5472.CAN-04-1013 (Pubitemid 39446929)
204. Hau P., Jachimczak P., Bogdahn U., Treatment of malignant gliomas with TGF- β 2 antisense oligonucleotides. Expert Review of Anticancer Therapy 2009 9 11 1663 1674 2-s2.0-71949123241 10.1586/ERA.09.138
205. Bogdahn U., Hau P., Stockhammer G., Venkataramana N. K., Mahapatra A. K., Suri A., Balasubramaniam A., Nair S., Oliushine V., Parfenov V., Poverennova I., Zaaroor M., Jachimczak P., Ludwig S., Schmaus S., Heinrichs H., Schlingensiepen K.-H., Targeted therapy for high-grade glioma with the TGF- β 2 inhibitor trabedersen: results of a randomized and controlled phase IIb study. Neuro-Oncology 2011 13 1 132 142 2-s2.0-79951602633 10.1093/neuonc/ noq142
206. Schmidt-Weber C. B., Blaser K., Regulation and role of transforming growth factor- β in immune tolerance induction and inflammation. Current Opinion in Immunology 2004 16 6 709 716 2-s2.0-7044284788 10.1016/j.coi.2004.09. 008 (Pubitemid 39423658)
207. Petrausch U., Jensen S. M., Twitty C., Poehlein C. H., Haley D. P., Walker E. B., Fox B. A., Disruption of TGF- β signaling prevents the generation of tumor-sensitized regulatory T cells and facilitates therapeutic antitumor immunity. The Journal of Immunology 2009 183 6 3682 3689 2-s2.0-70349339390 10.4049/jimmunol.0900560
208. Fecci P. E., Mitchell D. A., Whitesides J. F., Xie W., Friedman A. H., Archer G. E., Herndon J. E. II, Bigner D. D., Dranoff G., Sampson J. H., Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Research 2006 66 6 3294 3302 2-s2.0-33645502885 10.1158/0008-5472.CAN-05-3773
209. Randolph D. A., Fathman C. G., CD4+CD25+ regulatory T cells and their therapeutic potential. Annual Review of Medicine 2006 57 381 402 2-s2.0-32944456599 10.1146/annurev.med.57.121304.131337 (Pubitemid 43261997)
210. Humphries W., Wei J., Sampson J. H., Heimberger A. B., The role of tregs in glioma-mediated immunosuppression: potential target for intervention. Neurosurgery Clinics of North America 2010 21 1 125 137 2-s2.0-70450176686 10.1016/j.nec.2009.08.012
211. Powell D. J. Jr., Felipe-Silva A., Merino M. J., Ahmadzadeh M., Allen T., Levy C., White D. E., Mavroukakis S., Kreitman R. J., Rosenberg S. A., Pastan I., Administration of a CD25-directed immunotoxin, LMB-2, to patients with metastatic melanoma induces a selective partial reduction in regulatory T cells in vivo. The Journal of Immunology 2007 179 7 4919 4928 2-s2.0-40749114476
212. Mitchell D. A., Cui X., Schmittling R. J., Sanchez-Perez L., Snyder D. J., Congdon K. L., Archer G. E., Desjardins A., Friedman A. H., Friedman H. S., Herndon J. E. II, McLendon R. E., Reardon D. A., Vredenburgh J. J., Bigner D. D., Sampson J. H., Monoclonal antibody blockade of IL-2 receptor during lymphopenia selectively depletes regulatory T cells in mice and humans. Blood 2011 118 11 3003 3012 2-s2.0-80052919974 10.1182/blood-2011-02-334565
213. Fecci P. E., Ochiai H., Mitchell D. A., Grossi P. M., Sweeney A. E., Archer G. E., Cummings T., Allison J. P., Bigner D. D., Sampson J. H., Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function. Clinical Cancer Research 2007 13 7 2158 2167 2-s2.0-34247502076 10.1158/1078-0432.CCR-06-2070 (Pubitemid 46649886)
214. Agarwalla P., Barnard Z., Fecci P., Dranoff G., Curry W. T., Sequential immunotherapy by vaccination with GM-CSF-expressing glioma cells and CTLA-4 blockade effectively treats established murine intracranial tumors. Journal of Immunotherapy 2012 35 5 385 389 2-s2.0-84861233216 10.1097/CJI.0b013e3182562d59
215. Bedel R., Thiery-Vuillemin A., Grandclement C., Balland J., Remy-Martin J.-P., Kantelip B., Pallandre J.-R., Pivot X., Ferrand C., Tiberghien P., Borg C., Novel role for STAT3 in transcriptional regulation of NK immune cell targeting receptor MICA on cancer cells. Cancer Research 2011 71 5 1615 1626 2-s2.0-79952207466 10.1158/0008-5472.CAN-09-4540
216. Fujita M., Zhu X., Sasaki K., Ueda R., Low K. L., Pollack I. F., Okada H., Inhibition of STAT3 promotes the efficacy of adoptive transfer therapy using type-1 CTLs by modulation of the immunological microenvironment in a murine intracranial glioma. The Journal of Immunology 2008 180 4 2089 2098 2-s2.0-42149111675
217. Hussain S. F., Kong L.-Y., Jordan J., Conrad C., Madden T., Fokt I., Priebe W., Heimberger A. B., A novel small molecule inhibitor of signal transducers and activators of transcription 3 reverses immune tolerance in malignant glioma patients. Cancer Research 2007 67 20 9630 9636 2-s2.0-35448979864 10.1158/0008-5472.CAN-07-1243 (Pubitemid 47621208)
218. Wei J., Wang F., Kong L.-Y., Xu S., Doucette T., Ferguson S. D., Yang Y., McEnery K., Jethwa K., Gjyshi O., Qiao W., Levine N. B., Lang F. F., Rao G., Fuller G. N., Calin G. A., Heimberger A. B., MiR-124 inhibits STAT3 signaling to enhance T cell-mediated immune clearance of glioma. Cancer Research 2013 73 13 3913 3926 2-s2.0-84880062228 10.1158/0008-5472.CAN-12-4318
219. Banissi C., Ghiringhelli F., Chen L., Carpentier A. F., Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model. Cancer Immunology, Immunotherapy 2009 58 10 1627 1634 2-s2.0-68549112974 10.1007/s00262-009-0671-1
220. Jordan J. T., Sun W., Hussain S. F., DeAngulo G., Prabhu S. S., Heimberger A. B., Preferential migration of regulatory T cells mediated by glioma-secreted chemokines can be blocked with chemotherapy. Cancer Immunology, Immunotherapy 2008 57 1 123 131 2-s2.0-35748975652 10.1007/s00262-007-0336-x (Pubitemid 350043644)
221. Hirata F., Nomiyama S., Hayaishi O., Indoleamine 2,3 dioxygenase. Note I. Catalytic and molecular properties. Acta Vitaminologica et Enzymologica 1975 29 1-6 288 290 2-s2.0-0016642813
222. Hayaishi O., Hirata F., Fujiwara M., Senoh S., Tokuyama T., Indoleamine 2,3 dioxygenase. Note II. Biological function. Acta Vitaminologica et Enzymologica 1975 29 1-6 291 293 2-s2.0-0016586385
223. Uyttenhove C., Pilotte L., Théate I., Stroobant V., Colau D., Parmentier N., Boon T., Van den Eynde B. J., Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nature Medicine 2003 9 10 1269 1274 2-s2.0-0142137237 10.1038/nm934 (Pubitemid 37279849)
224. Friberg M., Jennings R., Alsarraj M., Dessureault S., Cantor A., Extermann M., Mellor A. L., Munn D. H., Antonia S. J., Indoleamine 2,3-dioxygenase contributes to tumor cell evasion of T cell-mediated rejection. International Journal of Cancer 2002 101 2 151 155 2-s2.0-0037056234 10.1002/ijc.10645 (Pubitemid 34970907)
225. Hwu P., Du M. X., Lapointe R., Do M., Taylor M. W., Young H. A., Indoleamine 2,3-dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation. The Journal of Immunology 2000 164 7 3596 3599 2-s2.0-0034176031 (Pubitemid 30169812)
226. Chung D. J., Rossi M., Romano E., Ghith J., Yuan J., Munn D. H., Young J. W., Indoleamine 2,3-dioxygenase-expressing mature human monocyte-derived dendritic cells expand potent autologous regulatory T cells. Blood 2009 114 3 555 563 2-s2.0-70149093957 10.1182/blood-2008-11-191197
227. Liu X., Shin N., Koblish H. K., Yang G., Wang Q., Wang K., Leffet L., Hansbury M. J., Thomas B., Rupar M., Waeltz P., Bowman K. J., Polam P., Sparks R. B., Yue E. W., Li Y., Wynn R., Fridman J. S., Burn T. C., Combs A. P., Newton R. C., Scherle P. A., Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity. Blood 2010 115 17 3520 3530 2-s2.0-77951718214 10.1182/blood-2009-09-246124
228. Sioud M., Sæbøe-Larssen S., Hetland T. E., Kærn J., Mobergslien A., Kvalheim G., Silencing of indoleamine 2,3-dioxygenaseenhances dendritic cell immunogenicity and antitumour immunity in cancer patients. International Journal of Oncology 2013 43 1 280 288 2-s2.0-84879682811 10.3892/ijo.2013.1922
229. Sørensen R. B., Hadrup S. R., Svane I. M., Hjortsø M. C., Straten P. T., Andersen M. H., Indoleamine 2,3-dioxygenase specific, cytotoxic T cells as immune regulators. Blood 2011 117 7 2200 2210 2-s2.0-79951820132 10.1182/blood-2010-06-288498
230. Balachandran V. P., Cavnar M. J., Zeng S., Bamboat Z. M., Ocuin L. M., Obaid H., Sorenson E. C., Popow R., Ariyan C., Rossi F., Besmer P., Guo T., Antonescu C. R., Taguchi T., Yuan J., Wolchok J. D., Allison J. P., Dematteo R. P., Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nature Medicine 2011 17 9 1094 1100 2-s2.0-80052493233 10.1038/nm.2438
231. Miyazaki T., Moritake K., Yamada K., Hara N., Osago H., Shibata T., Akiyama Y., Tsuchiya M., Indoleamine 2,3-dioxygenase as a new target for malignant glioma therapy: laboratory investigation. Journal of Neurosurgery 2009 111 2 230 237 2-s2.0-68849112548 10.3171/2008.10.JNS081141
232. Mitsuka K., Kawataki T., Satoh E., Asahara T., Horikoshi T., Kinouchi H., Expression of indoleamine 2,3-dioxygenase and correlation with pathological malignancy in gliomas. Neurosurgery 2013 72 6 1031 1039 2-s2.0-84878865462 10.1227/NEU.0b013e31828cf945
233. Wainwright D. A., Balyasnikova I. V., Chang A. L., Ahmed A. U., Moon K.-S., Auffinger B., Tobias A. L., Han Y., Lesniak M. S., IDO expression in brain tumors increases the recruitment of regulatory T cells and negatively impacts survival. Clinical Cancer Research 2012 18 22 6110 6121 2-s2.0-84869232447 10.1158/1078-0432.CCR-12-2130
234. Choi B. D., Fecci P. E., Sampson J. H., Regulatory T cells move in when gliomas say "I DO" Clinical Cancer Research 2012 18 22 6086 6088 2-s2.0-84869236294 10.1158/1078-0432.CCR-12-2801
235. Mattarollo S. R., Kenna T., Nieda M., Nicol A. J., Chemotherapy pretreatment sensitizes solid tumor-derived cell lines to V 24+ NKT cell-mediated cytotoxicity. International Journal of Cancer 2006 119 7 1630 1637 2-s2.0-33747511125 10.1002/ijc.22019 (Pubitemid 44258769)
236. Aymeric L., Apetoh L., Ghiringhelli F., Tesniere A., Martins I., Kroemer G., Smyth M. J., Zitvogel L., Tumor cell death and ATP release prime dendritic cells and efficient anticancer immunity. Cancer Research 2010 70 3 855 858 2-s2.0-76249128304 10.1158/0008-5472.CAN-09-3566
237. Zitvogel L., Apetoh L., Ghiringhelli F., Kroemer G., Immunological aspects of cancer chemotherapy. Nature Reviews Immunology 2008 8 1 59 73 2-s2.0-37549032137 10.1038/nri2216
238. Ramakrishnan R., Assudani D., Nagaraj S., Hunter T., Cho H.-I., Antonia S., Altiok S., Celis E., Gabrilovich D. I., Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice. The Journal of Clinical Investigation 2010 120 4 1111 1124 2-s2.0-77951178310 10.1172/JCI40269
239. Hong M., Puaux A.-L., Huang C., Loumagne L., Tow C., Mackay C., Kato M., Prévost-Blondel A., Avril M.-F., Nardin A., Abastado J.-P., Chemotherapy induces intratumoral expression of chemokines in cutaneous melanoma, favoring T-cell infiltration and tumor control. Cancer Research 2011 71 22 6997 7009 2-s2.0-81155154274 10.1158/0008-5472.CAN-11-1466
240. Tonon G., From oncogene to network addiction: the new frontier of cancer genomics and therapeutics. Future Oncology 2008 4 4 569 577 2-s2.0-55349137715 10.2217/14796694.4.4.569
241. Weinstein I. B., Joe A. K., Mechanisms of disease: oncogene addiction-a rationale for molecular targeting in cancer therapy. Nature Clinical Practice Oncology 2006 3 8 448 457 2-s2.0-33746961739 10.1038/ncponc0558 (Pubitemid 44203817)
242. Yan W., Zhang W., Jiang T., Oncogene addiction in gliomas: implications for molecular targeted therapy. Journal of Experimental and Clinical Cancer Research 2011 30 1, article no. 58 2-s2.0-79955975040 10.1186/1756-9966-30-58
243. Boni A., Cogdill A. P., Dang P., Udayakumar D., Njauw C.-N. J., Sloss C. M., Ferrone C. R., Flaherty K. T., Lawrence D. P., Fisher D. E., Tsao H., Wargo J. A., Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Research 2010 70 13 5213 5219 2-s2.0-77954373338 10.1158/0008-5472.CAN-10-0118
244. Koya R. C., Mok S., Otte N., Blacketor K. J., Comin-Anduix B., Tumeh P. C., Minasyan A., Graham N. A., Graeber T. G., Chodon T., Ribas A., BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy. Cancer Research 2012 72 16 3928 3937 2-s2.0-84865112760 10.1158/0008-5472.CAN-11-2837
245. Rosenberg S. A., Yang J. C., Restifo N. P., Cancer immunotherapy: moving beyond current vaccines. Nature Medicine 2004 10 9 909 915 2-s2.0-4644324025 10.1038/nm1100 (Pubitemid 39273730)